medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2006, Number 4

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2006; 19 (4)

Coccidioidomycosis. More than a regional disease

Laniado-Laborín R

Language: Spanish
References: 55
Page: 301-308
PDF size: 103.83 Kb.


ABSTRACT

Coccidioidomycosis is a fungal disease caused by two nearly identical species, Coccidioides immitis and C. posadasii.
It is endemic in the semiarid zones of the western hemisphere, especially in the southern United States of America and northern Mexico, although there are definite endemic regions in Central and South America; occasionally, it is diagnosed outside the endemic areas. In México most of the reported cases come from the northern states; however, not being a reportable disease, its true incidence is unknown.
More than 60 percent of the primary infections are asymptomatic; in the rest, the typical presentation includes systemic, dermatologic and respiratory signs and symptoms (“Valley Fever”). The acute pulmonary presentation is indistinguishable from a community acquired bacterial pneumonia. Extrapulmonary coccidioidomycosis occurs in one out of 200 primary infections. The most commonly affected sites include the central nervous system, bone, joints, skin and soft tissues.
Diagnosis is based in the isolation of the fungus by culture; direct observation of the spherules in exudates or in tissue is also considered diagnostic. There are serologic essays available for diagnosis.
Coccidioidomycosis includes a wide spectrum of clinical presentations, from the primary non complicated self-limited infection that usually resolves without specific treatment, to the acute disseminated forms usually fatal despite therapy. For this reason, the therapeutic strategies vary considerably from patient to patient. The most frequently used antimycotic drugs are amphotericin B, itraconazole and fluconazole.


REFERENCES

  1. Einstein HE, Johnson RH. Coccidioidomycosis: new aspects of epidemiology and therapy. Clin Infect Dis 1993;16:349-354.

  2. Posada A. Un nuevo caso de micosis fungoidea con psorospermias. Ann Círculo Médico Argentino 1892;15:585-596.

  3. Hector RF, Laniado-Laborin R. Coccidioidomycosis-A fungal disease of the Americas. PLoS Med 2005;2:2e.

  4. Catanzaro A. Coccidioidomycosis. Semin Respir Crit Care Med 2004;25:123-128.

  5. Stevens DA. Coccidioidomycosis. N Engl J Med 1995;332:1077-1082.

  6. Pappagianis D, Einstein H. Tempest from Tehachapi takes toll or Coccidioides immitis conveyed aloft and afar. West J Med 1978;129:527-530.

  7. Kirkland TN, Fierer J. Coccidioidomycosis: a reemerging infectious disease. Emerg Infect Dis 1996;2:192-199.

  8. Ajello L. Comparative ecology of respiratory mycotic disease agents. Bacteriol Rev 1967;31:6-24.

  9. González-Ochoa A. La coccidioidomicosis en México. Rev Invest Salud Pública (Mex) 1966;26:245-262.

  10. Laniado-Laborín R, Cárdenas-Moreno RP, Álvares-Cerro M. Tijuana: zona endémica de infección por Coccidioides immitis. Salud Pública Mex 1991;33:235-239.

  11. Padua A, Martinez-Ordaz VA, Velasco-Rodriguez VM, Lazo-Saenz JG, Cicero R. Prevalence of skin reactivity to coccidioidin and associated risk factors in subjects living in a northern city of Mexico. Arch Med Res 1999; 30:388-392.

  12. Mondragón-González R, Méndez-Tovar LJ, Bernal-Vázquez E, et al. Detección de infección por Coccidioides immitis en zonas del estado de Coahuila, México. Rev Argent Microbiol 2005;37:135-138.

  13. Bialek R, Kern J, Herrmann T, et al. PCR Assays for identification of Coccidioides posadasii based on the nucleotide sequence of the antigen 2/proline-rich antigen. J Clin Microbiol 2004;42:778-783.

  14. Fisher MC, Koenig GL, White TJ, Taylor JW. Molecular and phenotypic description of Coccidioides posadasii sp. nov., previously recognized as the non-Californian population of Coccidioides immitis. Mycology 2002;94:73-84.

  15. Castañón-Olivares LR, Aroch-Calderón A, Bazán-Mora E, Córdova-Martínez E. Coccidioidomicosis y su escaso conocimiento en nuestro país. Rev Fac Med UNAM 2004;47:145-148.

  16. Pappagianis D. Marked increase in cases of coccidioidomycosis in California: 1991, 1992, and 1993. Clin Infect Dis 1994;19 Suppl 1:S14-S18.

  17. Crum N, Lamb C, Utz G, Amundson D, Wallace M. Coccidioidomycosis outbreak among United States Navy SEALs training in a Coccidioides immitis-endemic area-Coalinga, California. J Infect Dis 2002;186:865-868.

  18. Cairns L, Blythe D, Kao A, et al. Outbreak of coccidioidomycosis in Washington state residents returning from Mexico. Clin Infect Dis 2000;30:61-64.

  19. Schneider E, Hajjeh RA, Spiegel RA, et al. A coccidioidomycosis outbreak following the Northridge, Calif, earthquake. JAMA 1997;277:904-908.

  20. Centers for Disease Control and Prevention (CDC). Coccidioidomycosis in workers at an archeologic site-Dinosaur National Monument, Utah, June-July 2001. MMWR Morb Mortal Wkly Rep 2001;50:1005-1008.

  21. Wanke B, Lazera M, Monteiro PC, et al. Investigation of an outbreak of endemic coccidioidomycosis in Brazil’s northeastern state of Piaui with a review of the occurrence and distribution of Coccidioides immitis in three other Brazilian states. Mycopathologia 1999;148:57-67.

  22. Crum NF, Lederman ER, Stafford CM, Parrish JS, Wallace MR. Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies. Medicine 2004;83:149-175.

  23. Ampel NM. Coccidioidomycosis in persons infected with HIV type 1. Clin Infect Dis 2005;41:1174-1178.

  24. Ampel NM, Dols CL, Galgiani JN. Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am J Med 1993;94:235-240.

  25. Jones JL, Fleming PL, Ciesielski CA, Hu DJ, Kaplan JE, Ward JW. Coccidioidomycosis among persons with AIDS in the United States. J Infect Dis 1995;171:961-966.

  26. Ampel NM, Ryan KJ, Carry PJ, Wieden MA, Schifman RB. Fungemia due to Coccidioides immitis. An analysis of 16 episodes in 15 patients and a review of the literature. Medicine 1986;65:312-321.

  27. Logan JL, Blair JE, Galgiani JN. Coccidioidomycosis complicating solid organ transplantation. Semin Respir Infect 2001;16:251-256.

  28. Braddy CM, Heilman RL, Blair JE. Coccidioidomycosis after renal transplantation in an endemic area. Am J Transplant 2006;6:340-345.

  29. Abbott KC, Hypolite I, Tveit DJ, Hshieh P, Cruess D, Agodoa LY. Hospitalizations for fungal infections after initiation of chronic dialysis in the United States. Nephron 2001;89:426-432.

  30. Ampel NM, Wieden MA, Galgiani JN. Coccidioidomycosis: clinical update. Rev Infect Dis 1989;11:897-911.

  31. Caldwell JW, Arsura EL, Kilgore WB, Garcia AL, Reddy V, Johnson RH. Coccidioidomycosis in pregnancy during an epidemic in California. Obstet Gynecol 2000;95:236-239.

  32. Chaturvedi V, Ramani R, Gromadzki S, Rodeghier B, Chang HG, Morse DL. Coccidioidomycosis in New York State. Emerg Infect Dis 2000;6:25-29.

  33. Lefler E, Weiler-Ravell D, Merzbach D, Ben-Izhak O, Best LA. Traveller’s coccidioidomycosis: case report of pulmonary infection diagnosed in Israel. J Clin Microbiol 1992;30:1304-1306.

  34. Pappagianis D. Epidemiology of coccidioidomycosis. Curr Top Med Mycol 1988;2:199-238.

  35. Munoz B, Castanon RL, Calderon I, Vazquez ME, Manjarrez ME. Parasitic mycelial forms of Coccidioides species in Mexican patients. J Clin Microbiol 2004;42:1247-1249.

  36. Laniado-Laborín R. Coccidioidomicosis: Clínica, diagnóstico y tratamiento. En: Méndez-Tovar LJ, editor. Actualidades en micología médica. 2ª ed. México: Facultad de Medicina, UNAM;2004.p. 269-276.

  37. Galgiani JN. Coccidioidomycosis. West J Med 1993;159:153-171.

  38. Castañeda-Godoy R, Laniado-Laborín R. Coexistencia de tuberculosis y coccidioidomicosis. Presentación de dos casos clínicos. Rev Inst Nal Enf Resp Mex 2002;15:98-101.

  39. Warlick MA, Quan SF, Sobonya RE. Rapid diagnosis of pulmonary coccidioidomycosis. Cytologic v potassium hydroxide preparations. Arch Intern Med 1983; 143:723-725.

  40. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis 2005;41:1217-1223.

  41. Drutz DJ. Amphotericin B in the treatment of coccidioidomycosis. Drugs 1983; 26:337-346.

  42. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996;22 Suppl 2:133-144.

  43. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003; 37(Suppl 3):188-224.

  44. Graybill JR, Stevens DA, Galgiani JN, Dismukes WE, Cloud GA. Itraconazole treatment of coccidioidomycosis. Am J Med 1990;89:282-290.

  45. Catanzaro A, Galgiani JN, Levine BE, et al. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. Am J Med 1995;98:249-256.

  46. Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med 2000; 133:676-686.

  47. Tucker RM, Denning DW, Dupont B, Stevens DA. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med 1990;112:108-112.

  48. Stevens DA. Adequacy of therapy for coccidioidomycosis. Clin Infect Dis 1997; 25:1211-1212.

  49. Blair JE, Logan JL. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis 2001;33:1536-1544.

  50. Woods CW, McRill C, Plikaytis BD, et al. Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: incidence, risk factors, and prevention. J Infect Dis 2000;181:1428-1434.

  51. Deresinski SC. Coccidioidomycosis: efficacy of new agents and future prospects. Curr Opin Infect Dis 2001;14:693-696.

  52. Prabhu RM, Bonnell M, Currier BL, Orenstein R. Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole. Clin Infect Dis 2004;39:e74-e77.

  53. Proia LA, Tenorio AR. Successful use of voriconazole for treatment of Coccidioides meningitis. Antimicrob Agents Chemother 2004;48:2341.

  54. Gonzalez GM, Tijerina R, Najvar LK, et al. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 2001;45:1854-1859.

  55. Pappagianis D. Seeking a vaccine against Coccidioides immitis and serologic studies: expectations and realities. Fungal Genet Biol 2001;32:1-9.




2020     |     www.medigraphic.com